核糖核酸酶含量测定作为乳腺肿瘤标志物的探索

以204例正常人,91例良性乳腺疾病患者为对照组,测定和分析了45例恶性乳腺肿瘤患者和32例乳腺癌癌前病变(22例乳腺囊性增生,10例乳腺导管上皮不典型增生)患者血清、尿液核糖核酸酶(RNase)含量及其部分乳腺癌患者术前后RNase含量的变化.结果表明:恶性肿瘤组RNase水平明显高于对照组,癌前病变组亦明显高于对照组,乳腺癌术后RNase含量较术前明显降低.提示RNase是乳腺肿瘤的良好标志物,测定RNase水平对乳腺癌早期诊断、鉴别诊断以及确定乳腺癌高发人群确有一定意义,同时可作为估计疗效的一项良好指标.

Measurement of RNase as a Tumor Marker of Breast Cancer

The levels of RNase in(Ribonuclease) serum and urine collected from 45 cases of breast malignant tumors and 32 cases of breast precancerous diseases (22 cases of breast fibrocystic hyperplasia, 10 cases of atypical hyperplasia of breast duct epithelia) were measured,and compared with those from 204 normal control group and 91 cases of breast benign disease . The changes of RNase level during preoperative and at preand postoperative periods were also measured in patients with breast cancer. The results showed that the levels of RNas in cases of malignant tumours and precancerous diseases were much higher than those in the both of the control groups. The level of RNase declined dramatically after operation. It is suggested that RNase can be considered as a good marker for breast cancer ,and might be of some value in making early diagnosis of breast cancer. On the other hand, RNase may be served as an useful indicator in evaluating the effectiveness of breast cancer treatment if patients have a high level of RNase before treatment.